Menu
Search
|

Menu

Close
X

Edge Therapeutics Inc EDGE.OQ (NASDAQ Stock Exchange Global Select Market)

0.70 USD
-0.01 (-1.69%)
As of Nov 16
chart
Previous Close 0.71
Open 0.71
Volume 6,956
3m Avg Volume 34,349
Today’s High 0.71
Today’s Low 0.69
52 Week High 17.76
52 Week Low 0.65
Shares Outstanding (mil) 31.33
Market Capitalization (mil) 20.88
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.214
FY17
-2.108
FY16
-1.345
FY15
-1.900
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
--
20.58
Price to Book (MRQ)
vs sector
0.67
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
0.00
13.84
LT Debt to Equity (MRQ)
vs sector
0.00
9.93
Return on Investment (TTM)
vs sector
-108.34
13.58
Return on Equity (TTM)
vs sector
-123.60
15.11

EXECUTIVE LEADERSHIP

Sol Barer
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Brian Leuthner
President, Chief Executive Officer, Director, Since
Salary: $500,000.00
Bonus: --
Isaac Blech
Independent Vice Chairman of the Board, Since 2013
Salary: --
Bonus: --
Andrew Saik
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
W. Bradford Middlekauff
Senior Vice President, General Counsel, Secretary, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

300 Connell Dr Ste 4000
BERKELEY HEIGHTS   NJ   07922-2817

Phone:

Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company's initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company's product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company's product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).

SPONSORED STORIES